dcc-2701 has been researched along with Neoplasms* in 2 studies
2 other study(ies) available for dcc-2701 and Neoplasms
| Article | Year |
|---|---|
Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.
The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib. Annually, it is estimated that around ∼20 000 new cases of tropomyosin receptor kinase (TRK) cancers are diagnosed, with the majority of cases exhibiting a TRK genomic rearrangement. In this Perspective, we discuss current development and clinical applications for TRK precision medicine by providing the following: (1) the biological background and significance of the TRK kinase family, (2) a compilation of known TRK inhibitors and analysis of their cocrystal structures, (3) an overview of TRK clinical trials, and (4) future perspectives for drug discovery and development of TRK inhibitors. Topics: Animals; Antineoplastic Agents; Catalytic Domain; Cell Line, Tumor; Drug Discovery; Humans; Mice, Inbred BALB C; Neoplasms; Precision Medicine; Protein Kinase Inhibitors; Rats, Sprague-Dawley; Receptor, trkA; Receptor, trkB; Receptor, trkC | 2019 |
Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2.
c-Met and VEGFR-2 have attracted interest as novel targets for treatment of various cancers. Aiming to develop potent dual c-Met and VEGFR-2 inhibitors, a series of pyrrolo[1,2-f][1,2,4]triazine derivatives were designed and synthesized. The majority of target compounds exhibited potent antiproliferative effect against c-Met addictive cancer cell lines with IC Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrroles; Triazines; Vascular Endothelial Growth Factor Receptor-2 | 2018 |